WO2018121802A1 - Composición vacunal que comprende un mutante de la interleucina-15 humana - Google Patents
Composición vacunal que comprende un mutante de la interleucina-15 humana Download PDFInfo
- Publication number
- WO2018121802A1 WO2018121802A1 PCT/CU2017/050008 CU2017050008W WO2018121802A1 WO 2018121802 A1 WO2018121802 A1 WO 2018121802A1 CU 2017050008 W CU2017050008 W CU 2017050008W WO 2018121802 A1 WO2018121802 A1 WO 2018121802A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- disease
- vaccine composition
- polypeptide
- overexpression
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 24
- 229960005486 vaccine Drugs 0.000 title claims abstract description 24
- 101001055157 Homo sapiens Interleukin-15 Proteins 0.000 title claims abstract description 12
- 102000056003 human IL15 Human genes 0.000 title claims abstract description 12
- 230000035772 mutation Effects 0.000 title abstract description 7
- 229920001184 polypeptide Polymers 0.000 claims abstract description 35
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 35
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 35
- 201000010099 disease Diseases 0.000 claims abstract description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 24
- 238000000034 method Methods 0.000 claims abstract description 21
- 230000002018 overexpression Effects 0.000 claims abstract description 15
- 238000011282 treatment Methods 0.000 claims abstract description 11
- 238000009169 immunotherapy Methods 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 7
- 102000003812 Interleukin-15 Human genes 0.000 claims abstract description 5
- 108090000172 Interleukin-15 Proteins 0.000 claims abstract description 5
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 4
- 206010028980 Neoplasm Diseases 0.000 claims abstract 2
- 230000009826 neoplastic cell growth Effects 0.000 claims abstract 2
- 108010002352 Interleukin-1 Proteins 0.000 claims description 86
- 102000000589 Interleukin-1 Human genes 0.000 claims description 85
- 102000004127 Cytokines Human genes 0.000 claims description 20
- 108090000695 Cytokines Proteins 0.000 claims description 20
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 12
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 7
- 206010025323 Lymphomas Diseases 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 5
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 239000005557 antagonist Substances 0.000 claims description 4
- 230000004927 fusion Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 201000005787 hematologic cancer Diseases 0.000 claims description 3
- 239000012646 vaccine adjuvant Substances 0.000 claims description 3
- 229940124931 vaccine adjuvant Drugs 0.000 claims description 3
- 239000000824 cytostatic agent Substances 0.000 claims description 2
- 230000001085 cytostatic effect Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 206010066476 Haematological malignancy Diseases 0.000 claims 1
- 108020004511 Recombinant DNA Proteins 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 208000014341 psoriasis 7 Diseases 0.000 claims 1
- 238000002649 immunization Methods 0.000 description 31
- 230000003053 immunization Effects 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 26
- 241001465754 Metazoa Species 0.000 description 17
- 230000003472 neutralizing effect Effects 0.000 description 17
- 210000002966 serum Anatomy 0.000 description 14
- 239000002671 adjuvant Substances 0.000 description 12
- 230000035755 proliferation Effects 0.000 description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 241000588724 Escherichia coli Species 0.000 description 9
- 238000010790 dilution Methods 0.000 description 9
- 239000012895 dilution Substances 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 230000004071 biological effect Effects 0.000 description 7
- 239000008055 phosphate buffer solution Substances 0.000 description 7
- 238000013207 serial dilution Methods 0.000 description 7
- 230000005875 antibody response Effects 0.000 description 6
- 238000006386 neutralization reaction Methods 0.000 description 6
- 239000012979 RPMI medium Substances 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 241000867607 Chlorocebus sabaeus Species 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 102000000588 Interleukin-2 Human genes 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000001516 cell proliferation assay Methods 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- SNBCLPGEMZEWLU-QXFUBDJGSA-N 2-chloro-n-[[(2r,3s,5r)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl]acetamide Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CNC(=O)CCl)[C@@H](O)C1 SNBCLPGEMZEWLU-QXFUBDJGSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- 125000000972 4,5-dimethylthiazol-2-yl group Chemical group [H]C([H])([H])C1=C(N=C(*)S1)C([H])([H])[H] 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000004556 Interleukin-15 Receptors Human genes 0.000 description 1
- 108010017535 Interleukin-15 Receptors Proteins 0.000 description 1
- 102100030703 Interleukin-22 Human genes 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102100021592 Interleukin-7 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 102000000585 Interleukin-9 Human genes 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000012564 Q sepharose fast flow resin Substances 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000005550 inflammation mediator Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 108010074108 interleukin-21 Proteins 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/00114—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55538—IL-12
Definitions
- the present invention relates to the branch of biotechnology, immunology and the pharmaceutical industry, in particular to active immunization with polypeptides comprising a mutated interleukin-1 (IL-15), for the treatment of diseases related to the envelope. -expression of IL-15.
- IL-15 mutated interleukin-1
- IL-1 5 The cytokine known as IL-1 5 is a 14-15 kDa glycoprotein, which was simultaneously identified by two groups, as a factor that activates T cells (Grabstein, KH et al., Science 1 994; 264: 965-8; Burton, JD et al., Proc. Nati. Acad. Sci. USA 1994; 91 (1 1): 4935-9).
- the messenger ribonucleic acid (RNA) (mRNA) of IL-15 is present in a wide variety of cells and tissues, however the protein is rarely found in the cells or in the culture supernatant of these cells that express the transcript, since there is a strong post-transcriptional control of its expression, at the level of translation and intracellular traffic (Bamford RN et al. J. Immunol 1998; 160: 4418-26; Kurys G. et al., J Biol C em 2000; 275: 30653-9).
- IL-1 5 The biological effects of IL-1 5 are mediated through binding to a receptor in the cell membrane, composed of three subunits, ⁇ , and ⁇ .
- the subunit (IL-15Ra) is specific for this cytokine, to which it binds with very high affinity (10 " Kd. 11 ).
- the ⁇ subunit is shared with IL-2, and the ⁇ subunit is a common receptor for several cytokines, such as IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21 (Burton JD et al. Proc. Nati. Acad. Sci. USA 1994, 91 (1 1) : 4935-9; Giri JG et al., EMBO J. 1995, 14: 3654-63).
- IL-1 5 is an immunostimulatory cytokine, which promotes the proliferation and functional activity of T, B and NK cells (Giri, JG et al., EMBO J. 1994, 13, 2822-30), activates neutrophils and modifies the secretion of monocinases (Girard D. et al., Blood. 1 996, 88: 31 76-84; Alleva DG et al., J. Immunol. 1997, 159 (6): 2941-51). In addition, it induces the proliferation of CD56 + NK cells, and acts together with IL-12 in the induction of interferon (IFN) ⁇ and tumor necrosis factor (TNFa) (Ross ME and Caligiuri MA Blood. 1997, 89: 910-8; Fehniger TA et al., Transplant Proc. 1999, 31: 1476-8).
- IFN interferon
- TNFa tumor necrosis factor
- IL-15 Unregulated expression or overexpression has been linked to the development of several diseases, including Crohn's disease (Kirman I. and Nielsen OH Am. J. Gastroenterol. 996, 91 (9): 1789 -94), psoriasis (Rückert R. et al., J. Immunol. 2000, 1 65: 2240-50), leukemia (Yamada Y. et al., Blood. 998, 91: 4265-72; Yamada Y y Kamihira S. Leuk Lymphoma. 1999, 35 (1-2): 37-45) and rheumatoid arthritis (RA), (Mclnnes IB Immunology Today. 1998, 19: 75-9).
- IL-15 induces the expression of IL-17 in the joint of patients with RA, stimulates the release of inflammation mediators, such as IL-6, IL-8, growth factor of granulocytes and macrophages (GM-CSF), and prostaglandin E 2 , suggesting that IL-1 5 plays an important role in the pathogenesis of RA (Ziolkowska M. et al, J Immunol. 2000, 1 64: 2832- 8).
- IL-15 antagonist molecules have been shown to be effective in animal models. Ruchatz et al. Generated a soluble fragment of the murine receptor ⁇ subunit, and demonstrated that administration of this fragment inhibits collagen-induced arthritis (AIC) in DBA / 1 mice (Ruchatz HJ Immunol. 1998, 160: 5654-60) .
- Genmab announced the study, in clinical phase I and II, of an anti-IL-15 antibody (HuMax-IL-1 5) (Patent No. US6177079). Although treatment was well tolerated, no significant efficacy was evidenced in a phase II study that involved 10 patients with RA (Baslund B. et al. Arthritis & Rheumatism. 2005, 52: 2686-92). Other studies have been conducted with a chimeric protein consisting of an IL-15 mutant and the Fe fragment of an immunoglobulin, which binds to cells that express the IL-15 receptor.
- CRB-15 This fusion protein, called CRB-15, has proven effective in a murine model of AIC, reporting that treatment with CRB-15 decreases the incidence and severity of the disease, and prevents the progression of arthritis once established ( Ferrari-Lacraz S. et al., J Immunol 2004, 1 73 (9): 5818-26).
- the present invention solves the problem set forth above, by providing a vaccine composition characterized in that it comprises a polypeptide containing a human IL-15 mutant identified as SEQ ID No. 1, at least one vaccine adjuvant and pharmaceutically acceptable excipients or vehicles.
- the IL-15 gene was isolated from monopods activated with lipopolysaccharides, and was amplified by polymerase chain reaction (PCR), using oligonucleotides specific for mutation in the sequence of IL-15. Specifically, Asp 8 and GIn 108 were mutated by Ser. The mutated polypeptide was obtained in said amino acid residues, hereinafter referred to as IL-15Mut, with a purity greater than 95%.
- the vaccine composition comprises a polypeptide containing the IL-1 5 mutant identified SEQ ID No. 1 (IL-1 5Mut) that is obtained by the recombinant deoxyribonucleic acid (DNA) pathway.
- IL-1 5Mut IL-1 5 mutant identified SEQ ID No. 1
- DNA deoxyribonucleic acid pathway
- the IL-1 5Mut polypeptide was obtained from E. coli, so it is not glycosylated, unlike the autologous protein present in humans.
- This mutated cytokine is not biologically active in the cell proliferation assay in CTLL-2, since it is not capable of inducing the growth of these cells, which are IL-15 dependent.
- IL-15Mut competes with native IL-15 for receptor binding, but does not induce signaling by having mutated Asp 8 and GIn 108 residues, which are key residues in the interaction with the ⁇ subunit and ⁇ of the receptor.
- This element constitutes an advantage with respect to the method proposed by Santos et al. (International Patent Application Publication No. WO 2004/032956), in terms of a lower occurrence of adverse events in treated patients, which are related to proinflammatory activity. of this cytokine.
- the polypeptide comprising the IL-15 mutant identified as SEQ ID No. 1, which is part of a vaccine composition is a fusion polypeptide.
- the fusion polypeptide containing the IL-15 mutant identified as SEQ ID No. 1 also comprises T epitopes, at a protein concentration of 200 ⁇ g.
- an IL-15 mutant was designed consisting of SEQ ID No. 1, recombinantly obtained, with molecular characteristics other than natural cytokine, in terms of the disulfide bridge arrangement. This element favors the development of the immune response by exposure of cryptic or immunodominant epitopes.
- non-human primates specifically Chlorocebus sabaeus green monkeys
- a vaccine composition comprising the IL-15Mut polypeptide, identified as SEQ ID No. 1, using aluminum hydroxide (referred to interchangeably as alumina) and the oil adjuvant Montanide TM ISA-51, generates a Antibody response that inhibits the biological activity of native IL-1 in CTLL-2 cells.
- This cell line used for neutralization assays, expresses the three subunits of the IL-1 5 receptor, and is dependent on this cytokine to proliferate (Eisenman J. et al. Cytokine. 2002; 20 (3): 121 - 9).
- the sera showed an inhibition of dose-dependent proliferation.
- This response is greater when compared to the group of animals that were immunized with the polypeptide identified as SEQ ID No. 2, IL-15 protein obtained in E. coli.
- immunization with a higher dose of the polypeptide of SEQ ID No. 1 (350 ⁇ ) generates a greater response of neutralizing antibodies, from 1 to 5 days after the second immunization.
- This aspect constitutes an advantage, since the desired effect is achieved with a smaller number of administrations of the vaccine composition of the invention.
- the vaccine composition of the invention can be administered by several routes, as is known to those skilled in this field of the art.
- the amount of vaccine antigen in the composition may vary, depending on the disease to be treated.
- the amount of antigen (polypeptide comprising a human interleukin-15 (IL-15) mutant identified as SEQ ID No. 1) is in the range of 200-500 ⁇ per dose of vaccine.
- compositions may contain vaccine adjuvants that are well known in current vaccinology, such as aluminum salts and water-in-oil emulsions, and others that are in development, with a view to generating in the patient the levels of antibodies against IL-15 that are required.
- vaccine adjuvants that are well known in current vaccinology, such as aluminum salts and water-in-oil emulsions, and others that are in development, with a view to generating in the patient the levels of antibodies against IL-15 that are required.
- the invention also discloses the use of a polypeptide comprising a human IL-15 mutant, identified as SEQ ID No. 1, to manufacture a medicament for active immunotherapy of a disease related to the overexpression of IL-15. . It is well known by those versed in this field of the art those diseases that present with an aberrant expression, or overexpression, of IL-15.
- polypeptide comprising a human IL-15 mutant, identified as SEQ ID No. 1, to manufacture a medicament for active immunotherapy of an autoimmune disease, selected from the group consisting of the RA, Crohn's disease, ulcerative colitis and psoriasis.
- said polypeptide is used for active immunotherapy of a disease related to the overexpression of IL-15, such as hematological malignancies.
- a disease related to the overexpression of IL-15 such as hematological malignancies.
- the hematologic malignancy is a leukemia or a lymphoma.
- the invention also provides a method for the treatment of diseases related to the overexpression of IL-15 characterized in that it comprises the administration to an individual in need of a therapeutically effective amount of a vaccine composition comprising a polypeptide containing a mutant. of human interleukin-15 (IL-15) identified as SEQ ID No. 1.
- IL-15 human interleukin-15
- said vaccine composition is suitable for administration in humans, and generates a neutralizing antibody response against autologous IL-15.
- the method of the invention which comprises active immunization with IL-15Mut (of SEQ ID No. 1) in a formulation suitable for generating neutralizing autoantibodies against IL-15, enables neutralization of unregulated amounts of this cytokine, in patients with autoimmune diseases and hematological malignancies.
- This method is superior to that proposed in International Patent Application Publication No. WO 2004/032956, if it is taken into account that the antigen used for active immunization lacks biological activity.
- the method of the invention is useful in the treatment of diseases related to the overexpression of IL-1 5, including RA, psoriasis and inflammatory bowel disease.
- the active immunotherapy method of the invention can be combined with the administration of other medications, such as anti-inflammatory or antagonists of other cytokines.
- these medications are, for example, steroid medications, such as corticosteroids, and disease modifiers (such as methotrexate).
- the method of the invention is also useful in the treatment of diseases such as hematologic malignancies, including leukemias and lymphomas.
- active immunotherapy using the vaccine composition of the invention can be combined with the administration, to the individual who requires it, of at least one pharmaceutically acceptable cytostatic.
- the method of the invention is advantageous, since the levels of antibodies generated in the patient themselves are more stable over time than those administered in a passive immunization.
- the frequency of application of the vaccine compositions comprising the IL-15 mutant is much lower than in a passive immunization with antibodies against the cytokine (in the method of the invention they are spaced for a longer time interval).
- the amount of protein per dose, and the amount of administrations that are required for vaccination are lower than those required for treatment with IL-15 antagonist molecules, which implies a lower production cost, and higher patients adherence to treatment.
- Immunization with the polypeptide identified as SEQ ID No. 1 generates antibodies with a greater neutralizing capacity than those obtained in the group that was immunized with the recombinant protein of SEQ ID No. 2.
- the use of an antigen that is not biologically active results in a lower frequency of unwanted events in patients treated with the vaccine that contains it.
- FIG. 1 Purity status of IL-15Mut. The chromatographic profiles obtained by phase high performance liquid chromatography are shown. Reverse (RP-HPLC) of: (A) the IL-15Mut and (B) the recombinant IL-15 obtained in E. coli, used as an antigen in the vaccine preparation.
- FIG. 1 Evaluation of the biological activity of IL-15Mut by the proliferation assay in CTLL-2.
- A Cell proliferation induced by serial dilutions of native IL-15 (R&D), IL-15Mut, recombinant IL-1 5 obtained in E. coli.
- B Cell proliferation curve in the presence of serial dilutions of IL-15Mut with a fixed concentration of native IL-1.
- FIG. 3 Evaluation by solid-phase immunoenzymatic assay (ELISA) of the anti-IL-15 antibody response in monkeys immunized with recombinant IL-15Mut and IL-15 using aluminum hydroxide (A) and Montanide TM ISA-51 (B) as adjuvants.
- the graphs show the average of the antibody titer values of the three animals of each experimental group, corresponding to 15 days after the second and third immunization.
- FIG. 4 Evaluation in CTLL-2 cells of the neutralizing capacity of the individual sera of the immunized animals, after the third immunization, using the alumina adjuvant.
- A Group IL-1 5
- B Group IL-15Mut at the dose of 200 ⁇ g
- C Group IL-15Mut at the dose of 350 g
- D placebo group.
- the line called Native IL-15 Dilution represents the maximum value of cell proliferation.
- the line called Minimum represents the minimum proliferation value corresponding to cells grown in culture medium without cytokine.
- Figure 5 Evaluation in CTLL-2 cells of the neutralizing ability of the mixture of sera from animals immunized with IL-15Mut and recombinant IL1 5.
- the neutralizing effect of each group is shown, 15 days after the second and third immunization, using the aluminum hydroxide adjuvant (A) or Montanide TM (B).
- the line called Native IL-15 Dilution represents the maximum value of cell proliferation.
- the line called Minimum represents the minimum proliferation value corresponding to cells grown in culture medium without cytokine.
- Example 1 Obtaining the IL-15Mut polypeptide in E. coli.
- DNA encoding human IL-15 was isolated by RT-PCR (reverse transcription - polymerase chain reaction, reverse transcription coupled to polymerase chain reaction) from monopods activated with lipopolysaccharides, and amplified by PCR ( T at 60 ° C, 25 cycles), using specific oligonucleotides for the mutation of Asp 8 and Gln 108 by Ser in the sequence of IL-1 5 (oligonucleotide 5 ' CAT GCC ATG GCA AAC TGG GTG AATGTA ATA AGT TCT TTG AAA and oligonucleotide 3 ' C GGGATCCCG TTA AGA AGT GTT GAT GAA CAT AGA GAC AAT).
- RT-PCR reverse transcription - polymerase chain reaction, reverse transcription coupled to polymerase chain reaction
- the PCR band was digested with Neo 1 / BamH I (Promega, USA), and cloned into an expression vector in E. coli.
- the renaturation process was carried out on a 1.6 x 40 cm column (GE Healthcare Life Sciences, USA), packed with Sephadex G-25 Fine (Pharmacia Biotech, Sweden) and equilibrated in 0.1 M Tris buffer and NaCI 0 ,15 M; pH 8.0; at a rate of 7 mL / min.
- the collected sample was applied to a 1.6x10cm column (GE Healthcare, USA) packed with Q Sepharose Fast Flow (GE Healthcare, USA), using a linear gradient elution from 0.2 M to 0.5 M NaCI, at a rate of 2 mL / min.
- the fraction corresponding to the elution with 0.5M NaCl was applied to a C 4 column (1 0 ⁇ , 1 x 25 cm, Vydac, USA), at a rate of 1 mL / min.
- the proteins were separated using a mobile phase containing 0.1% trifluoroacetic acid (TFA) and HPLC grade acetonitrile (AcN), using the following gradient: 0-30% 5 min; 30% 10 min; 30-40% 5 min; 40-50% 30 min; 50-60% 60 min; 60-80% 5 min at 2.5 mL / min. The separation was monitored at 226 nm. Protein concentration was determined by the Bradford method, following the manufacturer's instructions. The IL-15 protein without mutations was also obtained recombinantly in E. coli, as described above (Santos-Savio A. et al. Biotecn Aplic. 2000, 17: 221-4).
- Example 2 Determination of the purity of IL-15Mut by RP-HPLC.
- Example 3 Evaluation of the biological activity of IL-15Mut in the CTLL-2 cell line.
- the proliferation assay in the CTLL-2 cell line was used.
- the biological activity was measured by stimulation of the proliferation of these cells, using mitochondrial staining with 3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazoliob bromide (MTT) 3- [4, 5- Dimethylthiazol-2-yl] -2,5-diphenyltetrazolium bromide) (Mossman TJ Immunol. Methods. 1983; 65 (1 -2): 55-63), following the procedure described below.
- IL-15Mut Dilutions of IL-15Mut were co-incubated with 300 pg / mL of native IL-15, in a volume of 20 pL.
- CTLL-2 cells were previously washed 5 times with RPMI medium, and added to the plate, at a rate of 5x10 3 cells per well, in a volume of 50 pL. It was incubated for 72 h at 37 ° C, 5% C0 2 and 98% relative humidity. Cell viability was determined by staining with MTT.
- IL-15Mut was not biologically active, since it did not induce proliferation of CTLL-2 cells, unlike recombinant IL-15 (SEQ ID No. 2) and native IL-15, which stimulated a proliferation dose -dependent ( Figure 2).
- Example 5 Determination of anti-IL-15 antibodies in the serum of immunized animals.
- anti-ll-15 antibodies were made by an indirect ELISA type system, where the plate was coated with the polypeptide identified as SEQ ID No. 2 (1 pg / mL) in PBS, and incubated for 16 hours at 25 Q C. It was blocked with 1% bovine serum albumin (BSA) (Sigma-Aldrich, USA) at 1% in PBS for 90 min at 37 ° C. It was washed 3 times with wash solution (1x PBS + 0.05% Tween 20). Serial dilutions of the decomplemented sera were made, starting at 1: 5,000 in PBS; Tween 20 0.05% and BSA 0.01% and 100 pL were applied per well of the diluted serum, incubating 90 min at 37 ° C.
- BSA bovine serum albumin
- Example 6 Determination of the neutralizing capacity of sera from immunized animals.
- This IL-2-dependent line also proliferates in the presence of IL-15 (maximum proliferation is considered that achieved in cells treated with said native cytokine, at 300 pg / mL), while in the absence of cytokine the cells do not proliferate (minimum: cells grown in culture medium without IL-15).
- maximal proliferation is considered that achieved in cells treated with said native cytokine, at 300 pg / mL
- minimum cells grown in culture medium without IL-15.
- serial dilutions of the decomplemented sera were made in a 96-well culture plate in a volume of 30 pL of RPMI medium, supplemented with 10% SFB and gentamicin (50 pg / mL).
- 20 pL of native IL-15 (300 pg / mL) per well was added, and incubated at 37 ° C for 30 min.
- CTLL-2 cells were previously washed 5 times with RPMI medium, and added to the plate at a rate of 5x10 3 cells per well, in a volume of 50 pL.
- Figure 5 shows the neutralizing ability of mixing sera from animals immunized with IL-15Mut and recombinant IL15, determined in CTLL-2 cells.
- the sera correspond 1 to 5 days after the second and third immunization, using the aluminum hydroxide adjuvant or Montanide TM. It is appreciated that the sera possess neutralizing capacity after the third immunization, when 200 ⁇ g of recombinant IL-1 and IL-15 are administered. However, sera corresponding to the 350 ⁇ g dose showed neutralizing capacity 15 days after the second administration.
- Table 2 shows the Dl 50 values of the serum mixture corresponding to 15 days after the second and third immunization.
- the neutralization title for the three experimental groups is shown. It is shown that immunization with a higher dose (350 g) of IL-15Mut (SEQ ID No. 1) generates a greater neutralizing response, from 15 days after the second immunization, when alumina is used as an adjuvant.
- This aspect constitutes an advantage, taking into account that the desired effect could be achieved with a smaller number of administrations.
- the Dl 50 values for IL-15Mut are also higher than those achieved for recombinant IL-15, both after second and third administration. .
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17840472.9A EP3564264B1 (en) | 2016-12-30 | 2017-12-20 | Vaccine composition comprising a mutant of human interleukin-15 |
ES17840472T ES2892148T3 (es) | 2016-12-30 | 2017-12-20 | Composición vacunal que comprende un mutante de la interleucina-15 humana |
CN201780086587.4A CN110300762B (zh) | 2016-12-30 | 2017-12-20 | 包含人白介素-15的突变体的疫苗组合物 |
US16/474,913 US20200181254A1 (en) | 2016-12-30 | 2017-12-20 | Vaccine composition comprising a mutant of human interleukin-15 |
BR112019013542A BR112019013542A2 (pt) | 2016-12-30 | 2017-12-20 | composição de vacina, uso de um polipeptídeo, e, método para o tratamento de doenças associadas à superexpressão da il-15 |
MX2019007906A MX2019007906A (es) | 2016-12-30 | 2017-12-20 | Composicion vacunal que comprende un mutante de la interleucina-15 humana. |
RU2019122635A RU2745199C2 (ru) | 2016-12-30 | 2017-12-20 | Вакцинная композиция, содержащая мутантный человеческий интерлейкин-15 |
US17/531,914 US20220259300A1 (en) | 2016-12-30 | 2021-11-22 | Vaccine composition comprising a mutant of human interleukin-15 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU2016-0194 | 2016-12-30 | ||
CU2016000194A CU24546B1 (es) | 2016-12-30 | 2016-12-30 | Composición vacunal que comprende un mutante de la interleucina-15 humana |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/474,913 A-371-Of-International US20200181254A1 (en) | 2016-12-30 | 2017-12-20 | Vaccine composition comprising a mutant of human interleukin-15 |
US17/531,914 Division US20220259300A1 (en) | 2016-12-30 | 2021-11-22 | Vaccine composition comprising a mutant of human interleukin-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018121802A1 true WO2018121802A1 (es) | 2018-07-05 |
Family
ID=61188581
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CU2017/050008 WO2018121802A1 (es) | 2016-12-30 | 2017-12-20 | Composición vacunal que comprende un mutante de la interleucina-15 humana |
Country Status (9)
Country | Link |
---|---|
US (2) | US20200181254A1 (es) |
EP (1) | EP3564264B1 (es) |
CN (1) | CN110300762B (es) |
BR (1) | BR112019013542A2 (es) |
CU (1) | CU24546B1 (es) |
ES (1) | ES2892148T3 (es) |
MX (1) | MX2019007906A (es) |
RU (1) | RU2745199C2 (es) |
WO (1) | WO2018121802A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20230192797A1 (en) * | 2020-05-18 | 2023-06-22 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Human il-15 mutant and uses thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6001973A (en) | 1996-04-26 | 1999-12-14 | Beth Israel Deaconess Medical Center | Antagonists of interleukin-15 |
US6013480A (en) | 1995-02-22 | 2000-01-11 | Immunex Corporation | Antagonists of interleukin-15 |
WO2004032956A1 (es) | 2002-10-09 | 2004-04-22 | Centro De Ingenieria Genetica Y Biotecnologia | Composición vacunal que comprende interleucina-15 (il-15) |
WO2006017853A2 (en) * | 2004-08-11 | 2006-02-16 | Beth Israel Deaconess Medical Center, Inc. | Mutant interleukin-15-containing compositions and suppression of an immune response |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ570709A (en) * | 2003-06-13 | 2010-04-30 | Univ Pennsylvania | Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same |
ES2367027T3 (es) * | 2004-02-27 | 2011-10-27 | Inserm (Institut National De La Santé Et De La Recherche Medicale) | Sitio de unión de la il-15 para il-15ralfa y mutantes específicos de il-15 que tienen actividad agonista/antagonista. |
BRPI0519026A2 (pt) * | 2004-12-13 | 2008-12-23 | Cytos Biotechnology Ag | arranjos de antÍgeno de il-15 e usos dos mesmos |
CU23716A1 (es) * | 2008-09-30 | 2011-10-05 | Ct Ingenieria Genetica Biotech | Péptido antagonista de la actividad de la interleucina-15 |
JP7440102B2 (ja) * | 2018-06-22 | 2024-02-28 | キュージーン インコーポレイテッド | 新規インターロイキン-15(il-15)融合タンパク質およびその使用 |
-
2016
- 2016-12-30 CU CU2016000194A patent/CU24546B1/es unknown
-
2017
- 2017-12-20 MX MX2019007906A patent/MX2019007906A/es unknown
- 2017-12-20 ES ES17840472T patent/ES2892148T3/es active Active
- 2017-12-20 BR BR112019013542A patent/BR112019013542A2/pt unknown
- 2017-12-20 WO PCT/CU2017/050008 patent/WO2018121802A1/es unknown
- 2017-12-20 RU RU2019122635A patent/RU2745199C2/ru active
- 2017-12-20 EP EP17840472.9A patent/EP3564264B1/en active Active
- 2017-12-20 US US16/474,913 patent/US20200181254A1/en not_active Abandoned
- 2017-12-20 CN CN201780086587.4A patent/CN110300762B/zh active Active
-
2021
- 2021-11-22 US US17/531,914 patent/US20220259300A1/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6013480A (en) | 1995-02-22 | 2000-01-11 | Immunex Corporation | Antagonists of interleukin-15 |
US6168783B1 (en) | 1995-02-22 | 2001-01-02 | Immunex Corporation | Antagonists of interleukin-15 |
US6177079B1 (en) | 1995-02-22 | 2001-01-23 | Immunex Corporation | Antagonists of interleukin-15 |
US6001973A (en) | 1996-04-26 | 1999-12-14 | Beth Israel Deaconess Medical Center | Antagonists of interleukin-15 |
WO2004032956A1 (es) | 2002-10-09 | 2004-04-22 | Centro De Ingenieria Genetica Y Biotecnologia | Composición vacunal que comprende interleucina-15 (il-15) |
WO2006017853A2 (en) * | 2004-08-11 | 2006-02-16 | Beth Israel Deaconess Medical Center, Inc. | Mutant interleukin-15-containing compositions and suppression of an immune response |
Non-Patent Citations (32)
Title |
---|
ALLEVA D.G. ET AL., J. IMMUNOL., vol. 159, no. 6, 1997, pages 2941 - 294151 |
BAMFORD R.N. ET AL., J. IMMUNOL, vol. 160, 1998, pages 4418 - 44126 |
BASLUND B. ET AL., ARTHRITIS & RHEUMATISM, vol. 52, 2005, pages 2686 - 268692 |
BURTON J.D. ET AL., PROC. NATI. ACAD. SCI. USA, vol. 91, no. 11, 1994, pages 4935 - 46359 |
BURTON, J.D. ET AL., PROC. NATI. ACAD. SCI. USA, vol. 91, no. 11, 1994, pages 4935 - 4939 |
EISENMAN J. ET AL., CYTOKINE, vol. 20, no. 3, 2002, pages 121 - 1219 |
FEHNIGER T.A. ET AL., TRANSPLANT PROC., vol. 31, 1999, pages 1476 - 14768 |
FELDMANN M. ET AL., ANNU REV IMMUNOL., vol. 14, 1996, pages 397 - 440 |
FERRARI-LACRAZ S. ET AL., J IMMUNOL, vol. 173, no. 9, 2004, pages 5818 - 581826 |
FERRARI-LACRAZ SYLVIE ET AL: "Targeting IL-15 receptor-bearing cells with an antagonist mutant IL-15/Fc protein prevents disease development and progression in murine collagen-induced arthritis", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 173, no. 9, 1 November 2004 (2004-11-01), pages 5818 - 5826, XP002345721, ISSN: 0022-1767 * |
GIRARD D. ET AL., BLOOD, vol. 88, 1996, pages 3176 - 317684 |
GIRI J.G. ET AL., EMBO J., vol. 14, 1995, pages 3654 - 365463 |
GIRI, J.G. ET AL., EMBO J., vol. 13, 1994, pages 2822 - 282230 |
GRABSTEIN K.H. ET AL., SCIENCE, vol. 264, no. 5161, 1994, pages 965 - 9658 |
GRABSTEIN, K.H. ET AL., SCIENCE, vol. 264, 1994, pages 965 - 968 |
KANAI T ET AL., J IMMUNOL., vol. 157, no. 8, 1996, pages 3681 - 36817 |
KANEGANE H.; TOSATO G., BLOOD, vol. 88, no. 1, 1996, pages 230 - 2305 |
KIRMAN I.; NIELSEN O.H., AM. J. GASTROENTEROL., vol. 91, no. 9, 1996, pages 1789 - 178994 |
KURYS G. ET AL., J BIOL CHEM, vol. 275, 2000, pages 30653 - 306539 |
MCLNNES ).B. ET AL., NAT MED., vol. 3, 1997, pages 189 - 195 |
MCLNNES I.B. IMMUNOLOGY TODAY, vol. 19, 1998, pages 75 - 9 |
PETTIT D K ET AL: "STRUCTURE-FUNCTION STUDIES OF INTERLEUKIN 15 USING SITE-SPECIFIC MUTAGENESIS, POLYETHYLENE GLYCOL CONJUGATION, AND HOMOLOGY MODELING", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 272, no. 4, 24 January 1997 (1997-01-24), pages 2312 - 2318, XP002042891, ISSN: 0021-9258, DOI: 10.1074/JBC.272.4.2312 * |
RODRÍGUEZ Y. ET AL., BIOTECNOLOGÍA APLICADA, vol. 31, 2014, pages 291 - 2916 |
ROSS M.E.; CALIGIURI M.A., BLOOD, vol. 89, 1997, pages 910 - 9108 |
RUCHATZ H., J. IMMUNOL., vol. 160, 1998, pages 5654 - 60 |
RÜCKERT R. ET AL., J. IMMUNOL., vol. 165, 2000, pages 2240 - 224050 |
SANTOS-SAVIO A. ET AL., BIOTECN APLIC., vol. 17, 2000, pages 221 - 2214 |
VILLADSEN L S ET AL: "Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model", JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US, vol. 112, no. 10, 1 November 2003 (2003-11-01), pages 1571 - 1580, XP002293185, ISSN: 0021-9738, DOI: 10.1172/JCI200318986 * |
WILKINSON P.C.; LIEW F.Y., EXP MED., vol. 181, 1995, pages 1255 - 12559 |
YAMADA Y. ET AL., BLOOD, vol. 91, 1998, pages 4265 - 426572 |
YAMADA Y; KAMIHIRA S., LEUK LYMPHOMA, vol. 35, no. 1-2, 1999, pages 37 - 45 |
ZIOLKOWSKA M. ET AL., J IMMUNOL., vol. 164, 2000, pages 2832 - 2838 |
Also Published As
Publication number | Publication date |
---|---|
US20200181254A1 (en) | 2020-06-11 |
MX2019007906A (es) | 2019-09-04 |
CU20160194A7 (es) | 2018-08-06 |
RU2019122635A (ru) | 2021-02-01 |
US20220259300A1 (en) | 2022-08-18 |
EP3564264B1 (en) | 2021-09-08 |
EP3564264A1 (en) | 2019-11-06 |
RU2745199C2 (ru) | 2021-03-22 |
RU2019122635A3 (es) | 2021-02-01 |
ES2892148T3 (es) | 2022-02-02 |
CN110300762A (zh) | 2019-10-01 |
CN110300762B (zh) | 2023-05-02 |
CU24546B1 (es) | 2021-09-07 |
BR112019013542A2 (pt) | 2020-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2019202527B2 (en) | Compositions and methods for modulating gamma-c-cytokine activity | |
RU2711979C2 (ru) | Белковый комплекс интерлейкина 15 и его применение | |
Mohan et al. | CCL28 chemokine: an anchoring point bridging innate and adaptive immunity | |
JP4502580B2 (ja) | 敗血症の治療または予防のためのil−18阻害剤の使用 | |
ES2543915T3 (es) | Polipéptidos derivados de la IL-2 con actividad agonista para la terapia del cáncer e infecciones crónicas | |
ES2281175T3 (es) | Agonistas y antagonistas selectivos de il-2. | |
ES2328717T3 (es) | Peptido antagonista de interleuquina-15. | |
ES2884357T3 (es) | Modulación de la actividad de las citocinas gamma-c | |
TW201034685A (en) | Rheumatoid arthritis treatment agent | |
US20210324029A1 (en) | Stable modulators of gamma-c-cytokine activity | |
ES2267836T3 (es) | Chaperonina 10 de m. tuberculosis y sus usos. | |
WO2010037351A1 (es) | Péptido antagonista de la actividad de la interleucina - 15 | |
US20220259300A1 (en) | Vaccine composition comprising a mutant of human interleukin-15 | |
ES2319981T3 (es) | Composicion de vacuna que comprende interleucina-15 (il-15). | |
Rodríguez et al. | A modified variant of human Interleukin-15 as a novel antigen for active immunotherapy in rheumatoid arthritis | |
Rodríguez et al. | Una variante modificada de la interleucina-15 humana como antígeno novedoso para la inmunoterapia activa en la artritis reumatoide | |
JP2023508777A (ja) | インターロイキン-6に対して指向される免疫応答を誘導するための免疫原性複合体 | |
AU2002309887B2 (en) | Use of IL-18 inhibitors for the treatment or prevention of sepsis | |
AU2002309887A1 (en) | Use of IL-18 inhibitors for the treatment or prevention of sepsis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17840472 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112019013542 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2017840472 Country of ref document: EP Effective date: 20190730 |
|
ENP | Entry into the national phase |
Ref document number: 112019013542 Country of ref document: BR Kind code of ref document: A2 Effective date: 20190628 |